The average survival rate of female SLE patients is now significantly higher than before, but the specific survival period is still related to multiple factors such as the severity of the specific disease, treatment efficacy and the general physical condition of the patient, and needs to be considered comprehensively. For patients with mild disease, with only lesions such as rash, arthritis and oral ulcers, but without damage to important organs such as lungs and kidneys, their life expectancy is basically unaffected if they receive systematic and standardized treatment as early as possible. For patients who have already combined with lung, kidney, blood system, digestive system and other important system organs damage, the condition can also be stabilized through standardized treatment with glucocorticoids, immunosuppressants and other drugs. At present, the 10-year survival rate of SLE patients has reached 90%, and the 15-year survival rate can reach 80%, and most patients can work and live like normal people. Therefore, once diagnosed, female SLE patients should receive systematic and standardized treatment as soon as possible to fully control the disease progression and improve the survival cycle and quality of life.